2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 603

Characterization of Clinical Benefits in Subjects Classified As ACR20 Non-Responders at Week 104 of Apremilast Treatment: Subanalysis of 3 Long-Term, Phase III Trials

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 290

Characterization of Neutrophil Subsets and Neutrophil Extracellular Traps in Pyogenic Arthritis, Pyoderma Gangrenosum and Acne (PAPA) Syndrome

Innate Immunity and Rheumatic Disease Poster I

9:00AM-11:00AM: Abstract Number: 44

Characterization of Novel Stromal-Derived Autoantigens Recognized By RA Synovial Monoclonal Antibodies

B Cell Biology and Targets in Autoimmune Disease Poster

9:00AM-11:00AM: Abstract Number: 222

Characterization of Unexpected Autoantibody Specificities in American Indian SLE Patients

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 228

Characterizing Indigenous Community Engagement Patterns in Published Arthritis Studies: A Systematic Review of the Literature

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 641

Children with Treatment-Naive Enthesitis-Related Arthritis Have Decreased Fecal Abundance of Faecalibacterium Prausnitzii A2-165 and Bacteroides Fragilis: A Multi-Center Collaborative Study

Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster I

9:00AM-11:00AM: Abstract Number: 227

Chinese-American Rheumatology Patients Who Use Traditional Chinese-Medicine Have Worse Patient Reported Outcomes

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 401

Cigarette Smoking Dose-Dependently Facilitates the Onset of Arthritis and Aggravates Arthritis in Female Experimental Arthritis Mice

Rheumatoid Arthritis – Animal Models Poster I

9:00AM-11:00AM: Abstract Number: 776

Circulating Fibrocytes in Systemic Sclerosis Patients and Healthy Subjects: An in Vitro Study

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 579

Circulating MiR-145 As a Marker of Therapeutic Response to Anti-TNF Therapy in Patients with Ankylosing Spondylitis

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 82

CKD-506, a Novel Inhibitor of Histone Deacetylase 6 (HDAC6) Has a Therapeutic Potential in Rheumatoid Arthritis and Inflammatory Bowel Disease

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster I: The Variable World of Intercellular Signalling

9:00AM-11:00AM: Abstract Number: 47

Claudin-11 Regulates Bone Homeostasis Via Bidirectional EphB4-EphrinB2 Signaling

Biology and Pathology of Bone and Joint Poster I

9:00AM-11:00AM: Abstract Number: 490

Clinical and Biomarker Factors in the Prediction of Future Inflammatory Arthritis in ACPA Positive Subjects without Inflammatory Arthritis at Baseline

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 639

Clinical and Sonographic Analysis of Patients with Psoriasis without Musculoskeletal Complaints. Preeliminary Results of a Prospective Study: The PRE-Psa Cohort

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 520

Clinical and Structural Responses of Patients with Active Rheumatoid Arthritis (RA) Using Step-up Dosing of Tofacitinib in a Treat to Target Approach

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

«Previous Page
1
…
8
9
10
11
12
…
64
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].